introduction
Approximately 30% of pediatric non-Hodgkin's lymphomas (NHL) are lymphoblastic lymphomas (LLs) [1, 2] . Modern treatment approaches for advanced-stage pediatric LL are generally derived from successful therapies for acute lymphoblastic leukemia (ALL). This strategy was initially validated by a randomized Children's Cancer Study Group (CCG) trial, demonstrating that the LSA 2 L 2 regimen for ALL was superior to the alkylator-based COMP regimen for treatment of advanced-stage LL [3] . At least 75% of children with advancedstage LL are long-term event-free survivors when treated with contemporary treatment regimens [3] [4] [5] [6] . However, reliable prognostic factors for risk stratification to avoid over-or undertreatment have not been established for this patient population. Therefore, we sought to identify clinical features that are prognostically significant among 146 children with advancedstage LL treated at our institution over a period of 4 decades.
patients and methods

patients and treatment
From 1962 to 2002, 146 children with advanced-stage LL were evaluated and treated at St. Jude Children's Research Hospital. Disease stage was defined as previously described [7] . From 1962 through 1975, patients were treated with various multi-agent combinations, including some designed for the treatment of ALL. From 1975 through 1979, all stages of disease were treated on an NHL-specific protocol with cyclophosphamide, (Baxter, Deerfield, IL) vincristine (Hospira, Lake Forest, IL), Adriamycin, prednisone, 6-mercaptopurine, and low-dose methotrexate [8] . From 1979 through 1984, children with advanced-stage disease were treated on the Total 10 High protocol which was designed for high-risk ALL and consisted of an antimetabolite backbone plus teniposide and cytarabine pulses [9] . Advanced-stage disease was treated from 1985 through 1992 with Pediatric Oncology Group protocol therapy [10] . From 1992 to 2002, patients with advanced-stage disease were treated on NHL13 [4] , an institutional protocol similar to the total 13 regimen for T-cell ALL [11] .
statistical analysis
Presenting features at diagnosis were analyzed using the Chi-square test. The principal end point was event-free survival (EFS), measured from the start of therapy to the date of first treatment failure (relapse, death, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Distribution of EFS was estimated by the method of Kaplan and Meier and compared by using the log-rank test, stratified by treatment era where appropriate. Multivariable Cox proportional hazards regression models were used to assess whether EFS was associated with age at diagnosis, race, sex, mediastinal involvement, bone involvement, skin involvement, pleural effusion, CNS involvement, Murphy stage, or serum LDH activity.
results
presenting features
We studied the clinical course of 99 boys and 47 girls treated at our institution for stage III (n = 111) or stage IV (n = 35) LL. Table 1 summarizes patients' age, CNS involvement, serum LDH activity, and other presenting features. The prevalence of patient subgroups defined by these parameters did not differ significantly among the treatment eras (Table 1) .
clinical outcome
Treatment outcomes differed markedly according to the treatment approach. For example, the 5-year EFS estimate was 20.0% ± 8.0% (SE) for the 20 patients treated before 1975, when no uniform therapy had been established; the EFS estimate increased to 66.7% ± 9.3% for the 24 patients treated between 1979 and 1984 and then to 82.9% ± 6.1% for the 41 patients enrolled in the most recent trial, NHL13 (P < 0.0001; Figure 1 ) [4] . Adverse events are summarized in Table 2 .
predictors of outcome
In addition to treatment era, age at diagnosis was the only feature significantly associated with the outcome. Patients <10 years of age had a higher EFS estimate than did older patients (5-year EFS, 64.6% ± 5.9% versus 55.5% ± 5.6%; P = 0.014) ( Table 3 ). Both characteristics retained their independent prognostic significance (P < 0.0001 and P = 0.016, respectively) in the multivariable Cox proportional hazards regression model. When we examined the association of age (<10 years versus ≥10 years) with EFS within the three greater treatment eras, 1962-1979 ( pre-1975 and NHL75), 1979-1992 (St. Jude Total 10H and POG), and 1992-2002 (NHL13), the age category remained significant during the total 10 high-POG era (1979-1992), but there was less power to detect a significant difference within the pre-NHL75-NHL75 era (1975) (1976) (1977) (1978) (1979) or the NHL13 era (1992-2002), which had smaller patient numbers. In this regard, three of the five patients who experienced treatment failure on the NHL13 protocol were >10 years of age at diagnosis.
discussion
The clinical outcome for pediatric LL improved progressively over the sequential treatment eras at our institution. Although improved supportive care contributed to this progress (as shown by seven toxicity-associated early deaths during 1962-1979 but only two during later eras; Table 2 ), more effective lymphoma treatment was most likely the determinant factor. To this end, the first significant advance, implemented in the total 10 high regimen, was the incorporation of teniposide and cytarabine into an otherwise standard antimetabolite-based ALL regimen [9] . The subsequent NHL13 regimen [4] , derived from our total 13 protocol for high-risk ALL [12] , added high-dose methotrexate in both consolidation and continuation phases, a re-induction phase (comprising additional L-asparaginase), and weekly administration of rotating drug pairs during continuation therapy. NHL13 yielded a 5-year EFS estimate of 83%. Importantly, this regimen did not include prophylactic cranial irradiation; CNS prophylaxis was achieved through systemic chemotherapy (high-dose methotrexate, intravenous etoposide, and oral dexamethasone) and extended administration of intrathecal methotrexate, hydrocortisone, and cytarabine during continuation. Thus, as in ALL, outcome was improved by intensification of chemotherapy and refinement of CNS prophylaxis. NHL13 was not randomized to definitively original articles Annals of Oncology compare the contribution of individual features and many components are likely to have contributed to the excellent results. First, the addition of a re-induction phase with additional doses of L-asparaginase was probably important; in a randomized trial, Amylon et al [10] demonstrated that additional L-asparaginase improved the outcome of children with LL. Second, the incorporation of dexamethasone pulses throughout continuation is also likely to have been beneficial, as in childhood ALL [13] . Third, the use of etoposide during both the induction and continuation phases may have improved outcome, as suggested by this drug's known anti-ALL activity and its capacity to penetrate the blood-brain barrier [14] . Although the use of high-dose methotrexate in both consolidation and continuation (every 8 weeks for the first year) may have improved outcome in NHL13, there remains some 
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controversy regarding the role of high-dose methotrexate in the treatment of advanced stage LL. In this regard, high-dose methotrexate during consolidation offered no benefit over extended intrathecal chemotherapy in a Children's Oncology Group LL study [15] . Moreover, a randomized trial carried out by the Pediatric Oncology Group demonstrated no outcome advantage for those children with advanced stage LL who received high-dose methotrexate [16] . We sought to identify presenting prognostic features. After adjustment for treatment era, only patients' age at diagnosis NHL, non-Hodgkin's lymphoma; TOTXH, total 10 high. [5] . Therefore, there are currently no reliable prognostic factors for patients with advanced LL. Early response to therapy is the strongest independent predictor of treatment outcome in children with ALL [17] [18] [19] [20] [21] . The recent COG A5971 trial for LL used various diagnostic imaging modalities, including CT, gallium, and PET scanning, at several time points during induction therapy to determine whether early tumor response is related to treatment outcome [15] . However, diagnostic imaging studies have historically been unreliable in distinguishing necrotic from active residual masses [5] . PET imaging may improve our ability to detect residual disease, although confirmatory data for children with LL are lacking. The COG A5971 study also tested the prognostic significance of disease dissemination at diagnosis by using the same flow cytometric methods that are used to monitor minimal residual disease in children with T-cell ALL [17, [21] [22] [23] . The extent of minimal disseminated disease at diagnosis was found to be prognostically significant; patients with ≥1% circulating lymphoblasts had a significantly lower probability of EFS than did patients with a lesser extent of disseminated disease [24] . Based on these findings, our next study will use minimal disease measurements at diagnosis and during therapy for risk stratification.
funding
